| Nonsurvivors (n = 17) | Survivors (n = 72) | P-value* |
---|---|---|---|
Age, years | 69 (62.5,74.0) | 63 (53.3, 72.0) | 0.061 |
Male, n (%) | 6 (35.3) | 29 (40.3) | 0.705 |
BMI, kg/m2 | 26.02 (21.5,27.1) | 23.12 (21.1, 27.4) | 0.266 |
WHO-FC, n (%) | 0.045 | ||
 I–II | 1 (5.8) | 21 (29.2) |  |
 III-IV | 16 (94.2) | 51 (70.8) | |
6 MWD, m | 280 (187.5, 366.5) | 410 (325.0, 453.8) | 0.001 |
NT-pro-BNP, pg/ml | 1802 (1032.0, 2736.5) | 856 (387.5, 1908.5) | 0.006 |
HFrEF, n (%) | 1 (5.8) | 3 (4.2) | 0.759 |
HFpEF, n (%) | 13 (76.5) | 39 (54.2) | 0.093 |
VHD#, n (%) | 3 (17.6) | 30 (41.7) | 0.065 |
Comorbidities, n (%) | |||
Emphysema | 8 (47.1) | 26 (36.1) | 0.403 |
AF | 4 (23.5) | 23 (31.9) | 0.497 |
Hypertension | 7 (41.2) | 30 (41.7) | 0.971 |
Diabetes | 3 (17.6) | 12 (16.7) | 0.923 |
Renal insufficiency | 5 (29.4) | 5 (6.9) | 0.008 |
Medication | |||
Diuretics | 17 (100) | 68 (94.4) | 0.320 |
Anti-arrhythmias | 4 (23.5) | 19 (26.4) | 0.809 |
Anti-hypertensive | 7 (41.2) | 30 (41.7) | 0.971 |
Echocardiography | |||
RATD, cm | 4.3 (3.8,5.6) | 4.2 (3.8,5.0) | 0.381 |
RVEDTD, cm | 3.7 (3.1,4.2) | 3.6 (3.0,3.9) | 0.440 |
TAPSE, mm | 1.7 (1.6,2.2) | 1.8 (1.6,2.1) | 0.532 |
Pulmonary hemodynamics | |||
sPAP, mmHg | 64.0 (48.5,92.5) | 55.0 (45.0, 67.8) | 0.141 |
dPAP, mmHg | 22.0 (15.5,30.0) | 18.0 (15.0, 24.0) | 0.134 |
mPAP, mmHg | 42.0 (28.0,48.0) | 34.0 (28.0, 42.0) | 0.139 |
PAWP, mmHg | 18.0 (15.5,20.5) | 18.0 (16.0, 22.0) | 0.543 |
PVR, Wood U | 4.8 (2.5,6.4) | 2.9 (2.0, 4.1) | 0.023 |
DPG, mmHg | 2.0 (− 5.0,10.5) | − 1.0 (− 3.0, 3.0) | 0.029 |
TPG, mmHg | 17.0 (12.0,32.5) | 14.5 (10.0, 20.0) | 0.086 |
CO, L/min | 4.7 (4.1,5.6) | 5.2 (4.1, 6.0) | 0.334 |